{"hands_on_practices": [{"introduction": "A variant's frequency in the general population is a cornerstone of its clinical interpretation. Extremely rare variants are more likely to be pathogenic than common ones, which are generally considered benign polymorphisms. This exercise [@problem_id:4341305] provides hands-on practice with the foundational calculation of Minor Allele Frequency (MAF) from cohort data and its classification using standard rarity bins, a critical first step in any variant analysis pipeline.", "problem": "A cohort-based allele frequency assessment is being performed for an autosomal single-nucleotide variant in a population-scale dataset used for precision medicine. Consider the following scientifically realistic setting:\n\n- There are $10{,}000$ unrelated diploid human genomes, each contributing $2$ alleles at an autosomal locus. There are no missing genotypes and no copy-number alterations affecting the locus.\n- Across all chromosomes sampled in the cohort, the alternate allele is observed $50$ times.\n- Use the canonical definition of allele frequency: for any allele at a locus, its frequency in the cohort equals the count of that allele divided by the total number of alleles assayed at that locus.\n- The minor allele frequency is defined as the frequency of the less common allele among the reference and alternate alleles at that locus in the cohort.\n- For categorizing rarity, use the following Genome Aggregation Database (gnomAD)-style frequency bins, indexed by $1,2,3,4,5$:\n  - Bin $1$ (extremely rare): $0 < \\mathrm{MAF} < 10^{-4}$.\n  - Bin $2$ (very rare): $10^{-4} \\le \\mathrm{MAF} < 10^{-3}$.\n  - Bin $3$ (rare): $10^{-3} \\le \\mathrm{MAF} < 10^{-2}$.\n  - Bin $4$ (low-frequency): $10^{-2} \\le \\mathrm{MAF} < 10^{-1}$.\n  - Bin $5$ (common): $10^{-1} \\le \\mathrm{MAF} \\le 5 \\times 10^{-1}$.\n\nStarting only from these fundamental definitions and facts, compute the minor allele frequency for this variant and determine its rarity category by bin index using the bins above. Express the minor allele frequency as a decimal and round your result to four significant figures. Provide your final answer as a row matrix $\\begin{pmatrix} a & b \\end{pmatrix}$ where $a$ is the rounded minor allele frequency and $b$ is the integer bin index.", "solution": "The problem states an autosomal locus in a cohort of $10{,}000$ diploid genomes. For an autosomal locus, each diploid genome contributes $2$ alleles, so the total number of alleles assayed is\n$$\n2N = 2 \\times 10{,}000 = 20{,}000.\n$$\nThe alternate allele count is given as $50$. By the definition of allele frequency, the alternate allele frequency is\n$$\n\\mathrm{AF}_{\\text{alt}} = \\frac{50}{20{,}000} = 0.0025.\n$$\nThe reference allele frequency must sum with the alternate allele frequency to one, because there are only two alleles considered at the locus and no missing data:\n$$\n\\mathrm{AF}_{\\text{ref}} = 1 - \\mathrm{AF}_{\\text{alt}} = 1 - 0.0025 = 0.9975.\n$$\nThe minor allele frequency (MAF) is defined as the frequency of the less common allele among the two. Therefore,\n$$\n\\mathrm{MAF} = \\min\\{ \\mathrm{AF}_{\\text{alt}}, \\mathrm{AF}_{\\text{ref}} \\} = \\min\\{0.0025, 0.9975\\} = 0.0025.\n$$\nWe must round the minor allele frequency to four significant figures and express it as a decimal. The exact value $0.0025$ has two significant figures; to present four significant figures in decimal form, we retain trailing zeros:\n$$\n\\mathrm{MAF}_{\\text{rounded}} = 0.002500.\n$$\nNext, classify this $\\mathrm{MAF}$ using the specified Genome Aggregation Database (gnomAD)-style bins. We note that\n$$\n0.0025 = 2.5 \\times 10^{-3},\n$$\nwhich satisfies\n$$\n10^{-3} \\le 0.0025 < 10^{-2}.\n$$\nTherefore, it falls into Bin $3$ (rare).\n\nThe requested final answer format is a row matrix with the rounded minor allele frequency and the integer bin index:\n$$\n\\begin{pmatrix}\n0.002500 & 3\n\\end{pmatrix}.\n$$", "answer": "$$\\boxed{\\begin{pmatrix}0.002500 & 3\\end{pmatrix}}$$", "id": "4341305"}, {"introduction": "Genomic analyses in precision medicine, especially in oncology, often deal with impure samples containing a mixture of cell types. Accurately interpreting sequencing results requires deconvolving the signal from tumor cells and contaminating normal cells. This practice [@problem_id:4341294] demonstrates how to mathematically model the expected Variant Allele Fraction (VAF) based on key parameters like tumor purity and gene copy number, a crucial skill for making correct inferences from complex biological specimens.", "problem": "A tumor biopsy is profiled by targeted Next-Generation Sequencing (NGS). The sample consists of a mixture of tumor and normal cells, with tumor purity $p=0.6$. At a locus of interest, there is a clonal somatic single-nucleotide variant that is heterozygous in tumor cells, meaning the variant resides on exactly $c=1$ of the homologous chromosomes in every tumor cell. Normal cells are diploid. Sequencing at the locus yields $n=1000$ total reads, of which $x=280$ carry the variant allele.\n\nUse the following foundational bases:\n- In a mixture of cell populations, the expected variant allele fraction (VAF) equals the fraction of mutant alleles among all alleles contributing to the sample, assuming unbiased sequencing with respect to allele identity.\n- The number of alleles contributed by a cell equals its total copy number at the locus.\n- Each sequenced read can be modeled as an independent Bernoulli trial that reports the variant allele with probability equal to the underlying expected VAF at the locus.\n\nConsider two hypotheses for the tumor copy-number state at the locus:\n- Hypothesis $\\mathcal{H}_{N}$ (neutral): tumor cells are copy-number neutral (diploid total copy number $t=2$).\n- Hypothesis $\\mathcal{H}_{G}$ (gain): tumor cells carry a single-copy gain at the locus (trisomy total copy number $t=3$), and the variant remains present on only one tumor copy.\n\nNormal cells are diploid under both hypotheses. Derive the expected variant-allele probability $\\theta$ under each hypothesis from first principles of mixture contributions and allele counting. Then, using the binomial model for $x$ given $\\theta$, compute the Bayes factor favoring $\\mathcal{H}_{N}$ over $\\mathcal{H}_{G}$ and the posterior probability $P(\\mathcal{H}_{N} \\mid \\text{data})$ assuming equal prior probabilities for $\\mathcal{H}_{N}$ and $\\mathcal{H}_{G}$.\n\nReport the posterior probability for $\\mathcal{H}_{N}$ as a decimal, and round your answer to four significant figures.", "solution": "The core of the problem involves calculating the expected variant allele fraction (VAF) under two different biological hypotheses and then using Bayesian inference to determine which hypothesis is better supported by the sequencing data.\n\nThe general formula for the expected VAF, $\\theta$, in a sample with tumor purity $p$ is:\n$$\n\\theta = \\frac{p \\cdot c}{p \\cdot t + (1-p) \\cdot t_{norm}}\n$$\nwhere $c$ is the variant allele copy number in tumor cells, $t$ is the total copy number in tumor cells, and $t_{norm}$ is the total copy number in normal cells (here, $t_{norm}=2$). We are given $p=0.6$ and $c=1$.\n\nUnder hypothesis $\\mathcal{H}_{N}$ (copy-number neutral), tumor cells are diploid ($t=2$):\n$$\n\\theta_N = \\frac{0.6 \\cdot 1}{0.6 \\cdot 2 + (1-0.6) \\cdot 2} = \\frac{0.6}{1.2 + 0.8} = \\frac{0.6}{2} = 0.3\n$$\nUnder hypothesis $\\mathcal{H}_{G}$ (single-copy gain), tumor cells are triploid ($t=3$):\n$$\n\\theta_G = \\frac{0.6 \\cdot 1}{0.6 \\cdot 3 + (1-0.6) \\cdot 2} = \\frac{0.6}{1.8 + 0.8} = \\frac{0.6}{2.6} = \\frac{3}{13} \\approx 0.23077\n$$\nThe observed number of variant reads $x=280$ out of $n=1000$ total reads is modeled as a binomial random variable. The Bayes factor, $BF_{NG}$, favoring $\\mathcal{H}_{N}$ over $\\mathcal{H}_{G}$ is the ratio of the likelihoods of the data under each hypothesis:\n$$\nBF_{NG} = \\frac{P(\\text{data} \\mid \\mathcal{H}_{N})}{P(\\text{data} \\mid \\mathcal{H}_{G})} = \\frac{\\binom{n}{x} \\theta_N^x (1-\\theta_N)^{n-x}}{\\binom{n}{x} \\theta_G^x (1-\\theta_G)^{n-x}} = \\left(\\frac{\\theta_N}{\\theta_G}\\right)^x \\left(\\frac{1-\\theta_N}{1-\\theta_G}\\right)^{n-x}\n$$\nSubstituting the known values:\n$$\nBF_{NG} = \\left(\\frac{0.3}{3/13}\\right)^{280} \\left(\\frac{1-0.3}{1-3/13}\\right)^{720} = (1.3)^{280} \\left(\\frac{0.7}{10/13}\\right)^{720} = (1.3)^{280} (0.91)^{720}\n$$\nWe use logarithms to compute this value:\n$$\n\\ln(BF_{NG}) = 280\\ln(1.3) + 720\\ln(0.91) \\approx 280(0.262364) + 720(-0.094311) \\approx 73.4619 - 67.9039 \\approx 5.558\n$$\n$$\nBF_{NG} = \\exp(5.558) \\approx 259.3\n$$\nThe posterior probability of $\\mathcal{H}_N$, assuming equal prior probabilities ($P(\\mathcal{H}_N) = P(\\mathcal{H}_G) = 0.5$), is related to the Bayes factor by:\n$$\nP(\\mathcal{H}_N \\mid \\text{data}) = \\frac{BF_{NG}}{1+BF_{NG}}\n$$\nUsing a more precise calculation, $BF_{NG} \\approx 259.3585$.\n$$\nP(\\mathcal{H}_N \\mid \\text{data}) = \\frac{259.3585}{1+259.3585} = \\frac{259.3585}{260.3585} \\approx 0.996159\n$$\nRounding the result to four significant figures gives $0.9962$.", "answer": "$$\n\\boxed{0.9962}\n$$", "id": "4341294"}, {"introduction": "While population frequency provides a broad context, understanding a variant's impact often requires examining its behavior within families. This is particularly true for heritable diseases, where predicting risk for relatives is a key goal of precision medicine. This practice [@problem_id:4341280] explores the interplay between two central concepts: Mendelian segregation, which dictates how a variant is passed to offspring, and clinical penetrance, the probability that a carrier will actually manifest the disease.", "problem": "A clinically actionable autosomal dominant pathogenic variant is identified in a single heterozygous founder in a family under evaluation for cascade screening for a late-onset condition in the context of precision medicine. Assume the following foundational facts and definitions from Mendelian genetics and clinical penetrance:\n- Mendelian segregation: in a heterozygote-by-non-carrier mating, the probability that an offspring inherits the variant allele at each meiosis is $0.5$.\n- Penetrance: clinical penetrance is defined as the conditional probability of manifesting the disease phenotype given carriage of the pathogenic genotype, denoted $\\mathbb{P}(\\text{affected} \\mid \\text{carrier})$. For this variant, the age-appropriate cumulative penetrance at ascertainment is $0.70$ for all individuals in the pedigree (assume all individuals have attained the age at which cumulative penetrance reaches $0.70$).\n- No phenocopies: $\\mathbb{P}(\\text{affected} \\mid \\text{non-carrier}) = 0$.\n- Variant rarity: aside from the identified founder, there are no de novo events and no other sources of the variant in the pedigree. All non-founders mate with non-carriers. There is no consanguinity.\n\nThe pedigree consists of $3$ generations with a total of $20$ individuals:\n- Generation I: two founders; one is a confirmed heterozygous carrier of the variant, and the spouse is a confirmed non-carrier.\n- Generation II: the couple has $3$ biological children.\n- Generation III: each Generation II individual has $5$ biological children, yielding $15$ grandchildren in total.\n\nUsing only the core definitions above, compute the expected number of affected carriers in the entire $20$-person pedigree at the time of ascertainment. Express your final answer as a pure number with no units, and round your answer to four significant figures.", "solution": "The objective is to compute the expected number of affected carriers, $E_{AC}$, in the 20-person pedigree. By the linearity of expectation, this is the sum of the probabilities that each individual is an affected carrier.\n\nThe probability of an individual $i$ being an affected carrier is $\\mathbb{P}(\\text{affected}_i \\cap \\text{carrier}_i)$. This can be calculated as $\\mathbb{P}(\\text{affected}_i \\mid \\text{carrier}_i) \\times \\mathbb{P}(\\text{carrier}_i)$. The penetrance, $\\mathbb{P}(\\text{affected}_i \\mid \\text{carrier}_i)$, is given as $0.70$. Therefore, we need to find the probability of being a carrier, $\\mathbb{P}(\\text{carrier}_i)$, for each individual and sum the results.\n\nThe total expected number of affected carriers is:\n$$E_{AC} = 0.70 \\times \\sum_{i=1}^{20} \\mathbb{P}(\\text{carrier}_i)$$\nWe calculate the expected number of carriers by summing the probabilities for each generation.\n\n**Generation I (2 individuals):**\n- The founder is a confirmed carrier, so their probability is $1$.\n- The spouse is a confirmed non-carrier, so their probability is $0$.\n- Expected carriers in Generation I = $1 + 0 = 1$.\n\n**Generation II (3 individuals):**\n- Each individual is a child of a carrier/non-carrier mating. According to Mendelian segregation, the probability of inheriting the variant is $0.5$ for each child.\n- Expected carriers in Generation II = $3 \\times 0.5 = 1.5$.\n\n**Generation III (15 individuals):**\n- Each individual is a child of a Generation II person (who has a $0.5$ probability of being a carrier) and a non-carrier partner.\n- The probability for a Generation III individual to be a carrier is $\\mathbb{P}(\\text{parent is carrier}) \\times \\mathbb{P}(\\text{inherits} \\mid \\text{parent is carrier}) = 0.5 \\times 0.5 = 0.25$.\n- Expected carriers in Generation III = $15 \\times 0.25 = 3.75$.\n\nThe total expected number of carriers in the entire pedigree is the sum across all generations:\n$$ \\text{Expected Carriers} = 1 + 1.5 + 3.75 = 6.25 $$\nFinally, we compute the expected number of affected carriers by multiplying the total expected carriers by the penetrance:\n$$ E_{AC} = 0.70 \\times 6.25 = 4.375 $$\nThe result, $4.375$, already has four significant figures.", "answer": "$$\n\\boxed{4.375}\n$$", "id": "4341280"}]}